Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
Soulie C, Balde A, Fofana D, Charpentier C, Bonnafous P, Sourice J, De Monte A, Avettand-Fenoel V, Le Guillou-Guillemette H, Bocket L, Raymond S, Marque Juillet S, Trabaud MA, Montes B, Maillard A, Hartard C, Alessandri-Gradt E, Brochot E, Signori-Schmuck A, Assoumou L, Marcelin AG. Soulie C, et al. Among authors: charpentier c. J Antimicrob Chemother. 2024 Aug 1;79(8):1974-1984. doi: 10.1093/jac/dkae194. J Antimicrob Chemother. 2024. PMID: 38884154
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. Among authors: charpentier c. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group. Marcelin AG, et al. Among authors: charpentier c. Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9. Antimicrob Agents Chemother. 2010. PMID: 19901096 Free PMC article.
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D; ANRS 127 Study Group. Larrouy L, et al. Among authors: charpentier c. Antimicrob Agents Chemother. 2010 Jul;54(7):2910-9. doi: 10.1128/AAC.00194-10. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439606 Free PMC article. Clinical Trial.
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group. Recordon-Pinson P, et al. Among authors: charpentier c. Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7. Antimicrob Agents Chemother. 2010. PMID: 20530226 Free PMC article.
Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism.
Raymond S, Recordon-Pinson P, Saliou A, Delobel P, Nicot F, Descamps D, Marcelin AG, Flandre P, Calvez V, Masquelier B, Izopet J; ANRS AC11 Resistance Study Group. Raymond S, et al. J Antimicrob Chemother. 2011 Sep;66(9):1972-5. doi: 10.1093/jac/dkr224. Epub 2011 Jun 14. J Antimicrob Chemother. 2011. PMID: 21676905
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V. Marcelin AG, et al. Among authors: charpentier c. J Antimicrob Chemother. 2012 Jun;67(6):1475-8. doi: 10.1093/jac/dks047. Epub 2012 Feb 26. J Antimicrob Chemother. 2012. PMID: 22371439
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B; S AC11 Resistance Study Group. Recordon-Pinson P, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3. Antimicrob Agents Chemother. 2013. PMID: 23208718 Free PMC article.
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG. Lambert-Niclot S, et al. Among authors: charpentier c. J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29. J Antimicrob Chemother. 2013. PMID: 23361642
596 results